Oncolytics Total Revenue from 2010 to 2024

ONCY Stock  USD 0.94  0.01  1.05%   
Oncolytics Biotech Total Revenue yearly trend continues to be fairly stable with very little volatility. Total Revenue will likely drop to 0.00 in 2024. Total Revenue is the total amount of income generated by the sale of goods or services related to Oncolytics Biotech's primary operations. View All Fundamentals
 
Total Revenue  
First Reported
2000-03-31
Previous Quarter
0.0
Current Value
0.0
Quarterly Volatility
84.1 K
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Oncolytics Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncolytics Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 77 K, Interest Expense of 637.6 K or Selling General Administrative of 16.9 M, as well as many indicators such as Price To Sales Ratio of 66.83, Dividend Yield of 0.0 or PTB Ratio of 4.5. Oncolytics financial statements analysis is a perfect complement when working with Oncolytics Biotech Valuation or Volatility modules.
  
Check out the analysis of Oncolytics Biotech Correlation against competitors.
For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.

Latest Oncolytics Biotech's Total Revenue Growth Pattern

Below is the plot of the Total Revenue of Oncolytics Biotech over the last few years. Total revenue comprises all receipts Oncolytics Biotech generated from the sale of its products or services. It is the total amount of income generated by the sale of goods or services related to the company's primary operations. Oncolytics Biotech's Total Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncolytics Biotech's overall financial position and show how it may be relating to other accounts over time.
Total Revenue10 Years Trend
Slightly volatile
   Total Revenue   
       Timeline  

Oncolytics Total Revenue Regression Statistics

Arithmetic Mean323,435
Geometric Mean0.00
Coefficient Of Variation387.30
Mean Deviation603,746
Median0.00
Standard Deviation1,252,659
Sample Variance1.6T
Range4.9M
R-Value(0.31)
Mean Square Error1.5T
R-Squared0.1
Significance0.26
Slope(86,634)
Total Sum of Squares22T

Oncolytics Total Revenue History

20124.9 M
2011null
2010 1.0

About Oncolytics Biotech Financial Statements

Oncolytics Biotech investors use historical fundamental indicators, such as Oncolytics Biotech's Total Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Oncolytics Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Oncolytics Stock Analysis

When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.